open access

Vol 93, No 6 (2022)
Research paper
Published online: 2022-04-07
Get Citation

Influence of prenatal steroid therapy on the incidence of respiratory disorders in late premature infants

Natalia Czaplinska1, Monika Gruszfeld1, Joanna Schreiber-Zamora1, Natalia Goluchowska1, Piotr Rzepniewski1, Bronislawa Pietrzak2, Miroslaw Wielgos2, Bozena Kociszewska-Najman1
DOI: 10.5603/GP.a2022.0012
·
Pubmed: 35419798
·
Ginekol Pol 2022;93(6):478-481.
Affiliations
  1. Department of Neonatology, Medical University of Warsaw, Pediatric Hospital, Warsaw, Poland
  2. 1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland

open access

Vol 93, No 6 (2022)
ORIGINAL PAPERS Obstetrics
Published online: 2022-04-07

Abstract

Objectives: This study was conducted because of conflicting data on the role of corticosteroids administered before delivery in the late premature period. The aim of the study was to assess the frequency of respiratory disorders in 'late premature infants' and the impact of using prenatal steroid therapy.
Material and methods: The study included 513 newborns born between the 34–36 week of pregnancy. They were divided into two groups. In the first group, there were 439 newborns (85.58%) who did not receive prenatal steroid therapy, and in the second group, there were 74 newborns (14.42%) born after the prenatal steroid course. The frequency of occurrence of respiratory disorders requiring the use of non-invasive respiratory support methods as well as intubation and mechanical ventilation was compared in both groups.
Results: In the group of premature infants after steroid therapy 43/74 (58.12%) did not require respiratory support compared to the group of infants without prenatal steroid therapy where in 368/439 (83.8%) cases no respiratory disorders were found.
Conclusions: If there is a risk of preterm labor in the 34–36 week of pregnancy, the use of steroid therapy should be
considered. Steroidotherapy at this moment of gestation may not be such beneficial, like in the more premature delivery,
before 34 weeks of pregnancy.

Abstract

Objectives: This study was conducted because of conflicting data on the role of corticosteroids administered before delivery in the late premature period. The aim of the study was to assess the frequency of respiratory disorders in 'late premature infants' and the impact of using prenatal steroid therapy.
Material and methods: The study included 513 newborns born between the 34–36 week of pregnancy. They were divided into two groups. In the first group, there were 439 newborns (85.58%) who did not receive prenatal steroid therapy, and in the second group, there were 74 newborns (14.42%) born after the prenatal steroid course. The frequency of occurrence of respiratory disorders requiring the use of non-invasive respiratory support methods as well as intubation and mechanical ventilation was compared in both groups.
Results: In the group of premature infants after steroid therapy 43/74 (58.12%) did not require respiratory support compared to the group of infants without prenatal steroid therapy where in 368/439 (83.8%) cases no respiratory disorders were found.
Conclusions: If there is a risk of preterm labor in the 34–36 week of pregnancy, the use of steroid therapy should be
considered. Steroidotherapy at this moment of gestation may not be such beneficial, like in the more premature delivery,
before 34 weeks of pregnancy.

Get Citation

Keywords

prenatal steroid therapy; late preterm; RDS; respiratory support

About this article
Title

Influence of prenatal steroid therapy on the incidence of respiratory disorders in late premature infants

Journal

Ginekologia Polska

Issue

Vol 93, No 6 (2022)

Article type

Research paper

Pages

478-481

Published online

2022-04-07

Page views

1629

Article views/downloads

281

DOI

10.5603/GP.a2022.0012

Pubmed

35419798

Bibliographic record

Ginekol Pol 2022;93(6):478-481.

Keywords

prenatal steroid therapy
late preterm
RDS
respiratory support

Authors

Natalia Czaplinska
Monika Gruszfeld
Joanna Schreiber-Zamora
Natalia Goluchowska
Piotr Rzepniewski
Bronislawa Pietrzak
Miroslaw Wielgos
Bozena Kociszewska-Najman

References (14)
  1. Blencowe H, Vos T, Lee ACC, et al. Estimates of neonatal morbidities and disabilities at regional and global levels for 2010: introduction, methods overview, and relevant findings from the Global Burden of Disease study. Pediatr Res. 2013; 74(Suppl 1): 4–16.
  2. Ramadan MK, Hussein G, Saheb W, et al. Antenatal corticosteroids in the late preterm period: A prospective cohort study. J Neonatal Perinatal Med. 2016; 9(1): 15–22.
  3. Child Trends. Databank (2014). Preterm births. http://www.childtrends.org/?indicators=preterm-births (16.10.2020).
  4. Raju TNK, Higgins RD, Stark AR, et al. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics. 2006; 118(3): 1207–1214.
  5. Mally PV, Bailey S, Hendricks-Muñoz KD. Clinical issues in the management of late preterm infants. Curr Probl Pediatr Adolesc Health Care. 2010; 40(9): 218–233.
  6. Hibbard JU, Wilkins I, Sun L, et al. Consortium on Safe Labor. Respiratory morbidity in late preterm births. JAMA. 2010; 304(4): 419–425.
  7. Avery CM, Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972; 50(4): 515–525.
  8. Dixon CL, Too G, Saade GR, et al. Past and present: a review of antenatal corticosteroids and recommendations for late preterm birth steroids. Am J Perinatol. 2018; 35(13): 1241–1250.
  9. Chien LY, Ohlsson A, Seshia MMK, et al. Canadian Neonatal Network. Variations in antenatal corticosteroid therapy: a persistent problem despite 30 years of evidence. Obstet Gynecol. 2002; 99(3): 401–408.
  10. Gyamfi-Bannerman C, Thom E, Blackwell S, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. New England Journal of Medicine. 2016; 374(14): 1311–1320.
  11. Porto AM, Coutinho IC, Correia JB, et al. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ. 2011; 342: d1696.
  12. Yinon Y, Haas J, Mazaki-Tovi S, et al. Should patients with documented fetal lung immaturity after 34 weeks of gestation be treated with steroids? Am J Obstet Gynecol. 2012; 207(3): 222.e1–222.e4.
  13. Kamatkar S, Jobe A. Antenatal Late Preterm Steroids (ALPS): are we ready to accept it? J Perinatol. 2017; 37(6): 624–625.
  14. Gyamfi-Bannerman C, Thom EA, Gyamfi-Bannerman C, et al. NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med. 2016; 374(14): 1311–1320.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl